Ann Hynes
Stock Analyst at Mizuho
(4.36)
# 333
Out of 5,065 analysts
271
Total ratings
63.55%
Success rate
11.56%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDT Ardent Health | Maintains: Outperform | $20 → $13 | $8.94 | +45.41% | 3 | Nov 18, 2025 | |
| SGRY Surgery Partners | Maintains: Outperform | $28 → $22 | $15.84 | +38.89% | 3 | Nov 17, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $420 → $400 | $321.73 | +24.33% | 6 | Nov 4, 2025 | |
| HCA HCA Healthcare | Maintains: Outperform | $475 → $505 | $491.00 | +2.85% | 22 | Oct 27, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $575 → $655 | $591.82 | +10.68% | 5 | Oct 24, 2025 | |
| THC Tenet Healthcare | Maintains: Outperform | $194 → $225 | $191.96 | +17.21% | 16 | Oct 17, 2025 | |
| DGX Quest Diagnostics | Maintains: Outperform | $190 → $210 | $191.25 | +9.80% | 16 | Oct 17, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $320 | $265.64 | +20.46% | 16 | Oct 17, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $9 | $10.90 | -17.43% | 5 | Oct 17, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $155 → $174 | $167.64 | +3.79% | 3 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $32 | $34.59 | -7.49% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $430 | $319.97 | +34.39% | 21 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $345 | $227.10 | +51.92% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $40 | $36.50 | +9.59% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $88 | $78.03 | +12.78% | 11 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $22 | $15.18 | +44.93% | 12 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $225 | $224.90 | +0.04% | 13 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $173 → $225 | $164.56 | +36.73% | 16 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $330 | $141.56 | +133.12% | 9 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $23.10 | -35.06% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $209.48 | -42.72% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $20.23 | +38.41% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $114.35 | -16.92% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $278.09 | +38.44% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $231.92 | -13.76% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $2.13 | +12,482.16% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $866.03 | -41.69% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.31 | +4,247.83% | 1 | Sep 21, 2017 |
Ardent Health
Nov 18, 2025
Maintains: Outperform
Price Target: $20 → $13
Current: $8.94
Upside: +45.41%
Surgery Partners
Nov 17, 2025
Maintains: Outperform
Price Target: $28 → $22
Current: $15.84
Upside: +38.89%
Elevance Health
Nov 4, 2025
Maintains: Outperform
Price Target: $420 → $400
Current: $321.73
Upside: +24.33%
HCA Healthcare
Oct 27, 2025
Maintains: Outperform
Price Target: $475 → $505
Current: $491.00
Upside: +2.85%
Medpace Holdings
Oct 24, 2025
Maintains: Outperform
Price Target: $575 → $655
Current: $591.82
Upside: +10.68%
Tenet Healthcare
Oct 17, 2025
Maintains: Outperform
Price Target: $194 → $225
Current: $191.96
Upside: +17.21%
Quest Diagnostics
Oct 17, 2025
Maintains: Outperform
Price Target: $190 → $210
Current: $191.25
Upside: +9.80%
Labcorp Holdings
Oct 17, 2025
Maintains: Outperform
Price Target: $285 → $320
Current: $265.64
Upside: +20.46%
Fortrea Holdings
Oct 17, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $10.90
Upside: -17.43%
Charles River Laboratories International
Oct 17, 2025
Maintains: Neutral
Price Target: $155 → $174
Current: $167.64
Upside: +3.79%
Oct 17, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $34.59
Upside: -7.49%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $430
Current: $319.97
Upside: +34.39%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $345
Current: $227.10
Upside: +51.92%
Oct 9, 2025
Maintains: Neutral
Price Target: $28 → $40
Current: $36.50
Upside: +9.59%
Oct 9, 2025
Maintains: Outperform
Price Target: $76 → $88
Current: $78.03
Upside: +12.78%
Aug 14, 2025
Maintains: Neutral
Price Target: $32 → $22
Current: $15.18
Upside: +44.93%
Jul 25, 2025
Maintains: Outperform
Price Target: $190 → $225
Current: $224.90
Upside: +0.04%
Jul 25, 2025
Maintains: Outperform
Price Target: $173 → $225
Current: $164.56
Upside: +36.73%
Jul 11, 2025
Maintains: Outperform
Price Target: $400 → $330
Current: $141.56
Upside: +133.12%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $23.10
Upside: -35.06%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $209.48
Upside: -42.72%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $20.23
Upside: +38.41%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $114.35
Upside: -16.92%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $278.09
Upside: +38.44%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $231.92
Upside: -13.76%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $2.13
Upside: +12,482.16%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $866.03
Upside: -41.69%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.31
Upside: +4,247.83%